AR105087A1 - METHODS FOR THE TREATMENT OF WOMEN WITH HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) WITH THE BUPROPION AND TRAZODONA COMBINATION TREATMENT - Google Patents
METHODS FOR THE TREATMENT OF WOMEN WITH HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) WITH THE BUPROPION AND TRAZODONA COMBINATION TREATMENTInfo
- Publication number
- AR105087A1 AR105087A1 ARP160101856A ARP160101856A AR105087A1 AR 105087 A1 AR105087 A1 AR 105087A1 AR P160101856 A ARP160101856 A AR P160101856A AR P160101856 A ARP160101856 A AR P160101856A AR 105087 A1 AR105087 A1 AR 105087A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment
- hsdd
- bupropion
- drug
- trazodone
- Prior art date
Links
- 206010024419 Libido decreased Diseases 0.000 title abstract 9
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 title abstract 9
- 208000017020 hypoactive sexual desire disease Diseases 0.000 title abstract 9
- 238000000034 method Methods 0.000 title abstract 8
- 238000011282 treatment Methods 0.000 title abstract 7
- 229960001058 bupropion Drugs 0.000 title abstract 6
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 title abstract 6
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 title abstract 6
- 238000011284 combination treatment Methods 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 9
- 229940079593 drug Drugs 0.000 abstract 7
- 229960003991 trazodone Drugs 0.000 abstract 5
- 238000011269 treatment regimen Methods 0.000 abstract 4
- 239000002552 dosage form Substances 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 238000013265 extended release Methods 0.000 abstract 2
- 150000004677 hydrates Chemical class 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 230000002459 sustained effect Effects 0.000 abstract 2
- 238000013268 sustained release Methods 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Métodos de tratamiento de mujeres para el Trastorno del Deseo Sexual Hipoactivo (HSDD) con tratamientos diarios orales de combinaciones de bajas dosis y altas dosis de trazodona y bupropión. Reivindicación 1: Un método de tratamiento de una mujer con HSDD con un tratamiento de combinación que comprende al menos dos diferentes fármacos, en donde la mujer está en necesidad de un tratamiento para HSDD, en donde dicho método comprende: (a) la administración diaria a la mujer de un primer fármaco que tiene una concentración de dosis de 150 mg, en donde el primer fármaco es bupropión; (b) la administración diaria a la mujer de un segundo fármaco que tiene una concentración de dosis de 75 mg, en donde el segundo fármaco es trazodona; y (c) donde dicha administración de dicho primer fármaco y dicho segundo fármaco se encuentra de acuerdo con un régimen de tratamiento prescrito para el tratamiento de la mujer para HSDD. Reivindicación 4: El método de la reivindicación 1, en donde dicho régimen de tratamiento prescrito es por aproximadamente uno o más meses. Reivindicación 6: El método de la reivindicación 1, en donde dicho régimen de tratamiento prescrito es por aproximadamente uno o más años. Reivindicación 7: El método de la reivindicación 1, en donde el bupropión se encuentra en una forma de dosificación de liberación sostenida o extendida. Reivindicación 8: El método de la reivindicación 1, en donde la trazodona está en una forma de dosificación de liberación sostenida o extendida. Reivindicación 36: El uso de trazodona y bupropión en la fabricación de un medicamento para el tratamiento del desorden del deseo sexual hipoactivo (HSDD), en donde la trazodona está en una cantidad de aproximadamente 75 mg, y cualquiera de sus sales farmacéuticamente aceptables, ésteres, hidratos, solvatos, isómeros o profármacos del mismo, y bupropión está en una cantidad de aproximadamente 150 mg, y cualquiera sales farmacéuticamente aceptables, ésteres, hidratos, solvatos, isómeros y profármacos del mismo, en donde el medicamento es para ser administrado por vía oral, y en donde el tratamiento es para ser diario y continuado de acuerdo con un régimen de tratamiento prescrito.Methods of treatment of women for Hypoactive Sexual Desire Disorder (HSDD) with oral daily treatments of combinations of low doses and high doses of trazodone and bupropion. Claim 1: A method of treating a woman with HSDD with a combination treatment comprising at least two different drugs, wherein the woman is in need of a treatment for HSDD, wherein said method comprises: (a) daily administration to the woman of a first drug that has a dose concentration of 150 mg, wherein the first drug is bupropion; (b) the daily administration to the woman of a second drug having a dose concentration of 75 mg, wherein the second drug is trazodone; and (c) wherein said administration of said first drug and said second drug is in accordance with a prescribed treatment regimen for the treatment of women for HSDD. Claim 4: The method of claim 1, wherein said prescribed treatment regimen is for approximately one or more months. Claim 6: The method of claim 1, wherein said prescribed treatment regimen is for approximately one or more years. Claim 7: The method of claim 1, wherein the bupropion is in a sustained or extended release dosage form. Claim 8: The method of claim 1, wherein the trazodone is in a sustained or extended release dosage form. Claim 36: The use of trazodone and bupropion in the manufacture of a medicament for the treatment of hypoactive sexual desire disorder (HSDD), wherein trazodone is in an amount of approximately 75 mg, and any of its pharmaceutically acceptable salts, esters , hydrates, solvates, isomers or prodrugs thereof, and bupropion is in an amount of approximately 150 mg, and any pharmaceutically acceptable salts, esters, hydrates, solvates, isomers and prodrugs thereof, wherein the medicament is to be administered via the route. oral, and where the treatment is to be daily and continued according to a prescribed treatment regimen.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662351904P | 2016-06-17 | 2016-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105087A1 true AR105087A1 (en) | 2017-09-06 |
Family
ID=57758862
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160101856A AR105087A1 (en) | 2016-06-17 | 2016-06-21 | METHODS FOR THE TREATMENT OF WOMEN WITH HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) WITH THE BUPROPION AND TRAZODONA COMBINATION TREATMENT |
| ARP160101828A AR105047A1 (en) | 2016-06-17 | 2016-06-21 | METHODS FOR THE TREATMENT OF WOMEN BY THE HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) WITH A BUPROPION AND TRAZODONA COMBINATION TREATMENT |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160101828A AR105047A1 (en) | 2016-06-17 | 2016-06-21 | METHODS FOR THE TREATMENT OF WOMEN BY THE HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) WITH A BUPROPION AND TRAZODONA COMBINATION TREATMENT |
Country Status (9)
| Country | Link |
|---|---|
| KR (1) | KR20170142797A (en) |
| AR (2) | AR105087A1 (en) |
| AU (1) | AU2016204151A1 (en) |
| CA (1) | CA2933921A1 (en) |
| CL (1) | CL2016001597A1 (en) |
| MX (1) | MX2016008272A (en) |
| PE (1) | PE20180023A1 (en) |
| UY (1) | UY36742A (en) |
| WO (1) | WO2017218018A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5897864A (en) * | 1996-05-23 | 1999-04-27 | Cohen; Alan J. | Method for treating sexual dysfunction disorders with compositions containing ginkgo biloba |
| HUP0202719A3 (en) * | 2001-08-21 | 2006-01-30 | Pfizer Prod Inc | Pharmaceutical compositions for the treatment of female sexual dysfunctions |
| JP2007533686A (en) * | 2004-04-22 | 2007-11-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Novel pharmaceutical composition for the treatment of sexual disorder II |
| KR20080105104A (en) * | 2006-03-24 | 2008-12-03 | 와이어쓰 | New therapeutic combinations for the treatment of depression |
| SG10201908587PA (en) * | 2012-08-06 | 2019-10-30 | S1 Pharmaceuticals Inc | Treatment regimens |
-
2016
- 2016-06-20 WO PCT/US2016/038386 patent/WO2017218018A1/en active Application Filing
- 2016-06-20 MX MX2016008272A patent/MX2016008272A/en unknown
- 2016-06-20 UY UY0001036742A patent/UY36742A/en not_active Application Discontinuation
- 2016-06-20 KR KR1020160076915A patent/KR20170142797A/en not_active Application Discontinuation
- 2016-06-20 CL CL2016001597A patent/CL2016001597A1/en unknown
- 2016-06-20 AU AU2016204151A patent/AU2016204151A1/en not_active Abandoned
- 2016-06-20 CA CA2933921A patent/CA2933921A1/en not_active Abandoned
- 2016-06-20 PE PE2016000848A patent/PE20180023A1/en unknown
- 2016-06-21 AR ARP160101856A patent/AR105087A1/en unknown
- 2016-06-21 AR ARP160101828A patent/AR105047A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2016001597A1 (en) | 2017-10-06 |
| PE20180023A1 (en) | 2018-01-09 |
| CA2933921A1 (en) | 2017-12-17 |
| KR20170142797A (en) | 2017-12-28 |
| AU2016204151A1 (en) | 2018-01-18 |
| MX2016008272A (en) | 2017-12-18 |
| AR105047A1 (en) | 2017-08-30 |
| WO2017218018A1 (en) | 2017-12-21 |
| UY36742A (en) | 2016-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018004206A2 (en) | Pharmaceutical formulation for oral administration comprising a compound of 25-hydroxy vitamin d " | |
| AR096892A1 (en) | A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | |
| AR105027A1 (en) | METHODS OF TREATMENT OF LOCALLY ADVANCED OR METASTASIC BREAST CANCER USING ANTAGONISTS OF THE PD-1 AND TAXAN AXIS | |
| AR095338A1 (en) | NON-TOXIC TREATMENT METHOD FOR DRUG ABSTINENCE | |
| AR090885A1 (en) | USE OF LAQUINIMOD IN HIGH DOSE FOR THE TREATMENT OF MULTIPLE SCLEROSIS | |
| DOP2016000254A (en) | PHARMECEUTIC FORMULATIONS OF PAN-RAF QUINASE INHIBITOR, PROCEDURES FOR THEIR PREPARATION, AND METHODS OF USE. | |
| CL2021001636A1 (en) | Pharmaceutical composition for the treatment of pulmonary arterial hypertension | |
| AR098832A1 (en) | USE OF LAQUINIMOD TO DELAY THE PROGRESSION OF HUNTINGTON'S DISEASE | |
| MX2015009546A (en) | Increased dosage of efavirenz for the treatment of cancer. | |
| UY31826A (en) | PEPTIDE COMPOUND AND ITS USE | |
| CO2020001887A2 (en) | Synergistic pharmaceutical combination of the active enantiomer s-ketorolac and gabapentin for the treatment of neuropathic pain | |
| AR105087A1 (en) | METHODS FOR THE TREATMENT OF WOMEN WITH HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) WITH THE BUPROPION AND TRAZODONA COMBINATION TREATMENT | |
| PE20221338A1 (en) | METHODS OF TREATMENT OF SMALL CELL LUNG CANCER WITH FORMULATIONS OF LURBINECTEDIN | |
| DOP2022000004A (en) | PHARMACEUTICAL COMPOSITIONS RESISTANT TO THE DISCHARGE OF DOSES THAT INCLUDE VENIRUNAD | |
| ECSP15033649A (en) | A COMBINED MEDICINAL PRODUCT INCLUDING PHENYLEPHRINE AND PARACETAMOL | |
| UY38948A (en) | DOSAGE REGIME FOR ANTI-DLL3 AGENTS | |
| MX2018005298A (en) | Dosage regimen for a phosphatidylinositol 3-kinase inhibitor. | |
| CO2018013792A2 (en) | Dosing regimens of vortioxetine for the rapid onset of the antidepressant effect | |
| CL2021000882A1 (en) | Formulations and methods for treating chemotherapy-induced nausea and vomiting. | |
| TN2016000179A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. | |
| AR108792A1 (en) | COMPOSITIONS THAT INCLUDE TIMOLOL | |
| AR113906A1 (en) | CLADRIBINE REGIME TO TREAT PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS | |
| AR101227A1 (en) | COMBINATIONS OF A N-TIAZOLIL-4-PHENOXIBENCENOSULFONAMIDE DERIVATIVE AND A PHARMACEUTICALLY ACTIVE AGENT SELECTED FROM GABAPENTINE AND PREGABALINE TO TREAT PAIN | |
| BR112018002433A2 (en) | pharmaceutical composition for migraine treatment | |
| AR114012A1 (en) | METHOD OF PROVIDING CELIPROLOL THERAPY TO A PATIENT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |